

Humber Area Prescribing Committee

Date / Time	4 th October 2023 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to send papers to Dr Pothina (items ratified after meeting)

Attendance	<p>Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR)</p> <p>Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)</p> <p>Luke Storr – Senior Pharmacy Technician, HUTH (LS)</p> <p>Ruckaiya Karim, Deputy Chief Pharmacist, HUTH (RK) (attending for Joanne Goode)</p> <p>Prof A Morice, Professor of Respiratory Medicine HUTH, Chair of HUTH D&TC- (AM)</p> <p>Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc)</p> <p>Alexandra Curran, Medicines Optimisation Pharmacist, NECS (AC)</p> <p>Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS)</p> <p>Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB)</p> <p>Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK)</p> <p>Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF)</p> <p>Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)</p> <p>Natasha Suffill- Lead Clinical Pharmacist CHCP (NS) (attending for Emma Baggaley)</p> <p>Daniel Newsome- Principal Pharmacist RDTC (DN) (from 2pm)</p> <p>Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH)</p> <p>Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA)</p> <p>Dr Pratik Basu- GP- The Birches medical practice (PB)</p> <p>Dr Rolan Schreiber, Professional Secretary LMC (RSx)</p>
-------------------	--

Apologies

Simon Priestley- Chief Pharmacist, NLAG (SP)

Joanne Goode – Chief Pharmacist – HUTH (JG) – RK in attendance

Emma Baggaley - Assistant Director Medicines Management CHCP – NS in attendance

Agenda Number	Item	Discussion	Action	Lead	Due Date
2023.10.01	Apologies	Noted above			
2023.10.02	Declarations of interest	None			
2023.10.03	Minutes of previous meeting	Accepted as true record			
2023.10.04	Action Tracker	Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies) June 2023: In progress July 2023: In progress August 2023: Received info from CHCP/HFT, JM to prepare new document September 2023: In progress October 2023: In progress	Ongoing	AK/JM	11/23
		Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydroxychloroquine SCF September update: JM to contact Rachel Ainger October update: October 2023: JM attended ICB wide meeting regarding preparing ICB SCF and progressing monitoring. JM/AK to continue to attend meeting to progress SCF	Ongoing	JM	12/23
		Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs)	Ongoing	JM	12/23

		<p>JM to provide RS information on number of patients in NEL/NL December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL). March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update April update: Riluzole to JM to update websites to include NL May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review June update: Modafinil still waiting on NL, JM to review mycophenolate for July guideline group July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group September update: For September guideline group October 2023 update: For November Guideline group</p> <p>Outstanding actions from HERPC Renal repatriation: November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time. December update – Not met with renal yet. March update – Updating business case. May update – to meet with NHSE August update – not yet met with NHSE September update - not yet met with NHSE October update: not yet met with NHSE</p> <p>Ratification of joint formulary To add chapter 1 to netformulary (and remove HERPC chapter when complete) September 2023 update: currently available products; to add new products still and remove HERPC chapter October 2023 update: net Formulary update complete and links built in. Removing HERPC chapter 1 still outstanding</p> <p>Blueteq</p>	Ongoing	JM	12/23
		<p>Ratification of joint formulary To add chapter 1 to netformulary (and remove HERPC chapter when complete) September 2023 update: currently available products; to add new products still and remove HERPC chapter October 2023 update: net Formulary update complete and links built in. Removing HERPC chapter 1 still outstanding</p>	Ongoing	JM/AK/LS	11/23
		<p>Blueteq</p>	Ongoing	JM	12/23

	<p>Non-compliance to NICE guidance in acute trusts and financial impact</p> <p>June update: JM to submit ustekinumab report in gastroenterology HUTH when approved</p> <p>JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved</p> <p>July update: JM to update next time.</p> <p>August update: no further update, infliximab audit in HUTH started</p> <p>September update: HUTH audit still ongoing</p> <p>October update: HUTH audits still ongoing</p> <p>Ratification of guidelines and SCFs</p> <p>Infliximab in ASUC – to add additional information and re-present when updated</p> <p>July update: JM to update for next meeting, AK provided info requested</p> <p>August update: Awaiting information from pathology</p> <p>September update: To finalise document and send to chief pharmacists for comment</p> <p>October update: Sent to chief pharmacists for comment</p> <p>AOB – ondansetron</p> <p>Pathway to be referred to NLAG M&T and to appropriate meeting in Northern Lincolnshire places</p> <p>August update – M&T cancelled due to junior doctor strikes</p> <p>October update – Awaiting pathway to presented at M&T</p> <p>Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX</p> <p>August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway; to enable JM to start writing paper.</p> <p>September update: September D&TC next week, further updates to pathway needed</p> <p>October update: Awaiting updated pathway</p> <p>Outstanding actions from HERPC: Hydroxychloroquine SCF monitoring</p> <p>August update: JM attended PE&CE</p>	Ongoing	JM	11/23
		Ongoing	AK	12/23
		Ongoing	JM	12/23
		Action complete	JM	11/23

		<p>October update: to close this action and progress with ICB shared care work</p> <p>Outstanding actions from HERPC: Dienogest pathway JM to update pathway for September guideline group October update: on agenda action complete</p> <p>Ratification of guidelines and SCFs: ICB Continuous Blood Glucose Monitoring To update APC website, joint formulary and HERPC formulary/webpages with this guidance and Dexcom1 classification September 2023 update: everything linked but request to update Dexcom1 as error. October 2023: Action complete</p> <p>Ratification of guidelines and SCFs: Sick Day Guidance in T2DM JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team October 2023: ongoing</p> <p>Ratification of guidelines and SCFs: Amiodarone SCF JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG.</p> <p>Ratification of guidelines and SCFs JM/AK to update formulary to match all asthma 3 guideline October update: ongoing</p> <p>Ratification of guidelines and SCFs JM/AK to update links in netFormulary when asthma published on ICB website October update: action complete</p> <p>Ratification of guidelines and SCFs JM to remove HERPC/NLAPC asthma guidance from HERPC website/NLAPC website when new guidance published October update: action complete</p>	<p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p>	<p>JM</p> <p>JM/LS</p> <p>JM</p> <p>JM</p> <p>JM/AK</p> <p>JM</p> <p>JM</p>	<p>10/23</p> <p>10/23</p> <p>11/23</p> <p>11/23</p> <p>11/23</p> <p>10/23</p> <p>10/23</p>
--	--	---	--	---	--

		<p>Ratification of joint formulary JM to contact Faisal Majothi to confirm pump patient comment October update: action complete</p> <p>Ratification of joint formulary JM to link blood glucose formulary through when final version available October update: action complete</p> <p>RTDC updates JM/AK to update joint formulary October update: action complete</p> <p>RTDC updates JM/LS to update HERPC red list October update: action complete</p>	Action complete	JM	10/23
			Action complete	JM	10/23
			Action complete	JM/AK	10/23
			Action complete	JM/LS	10/23
2023.08.05	Traffic Light Status	<p>Bulevirite- Approved as RED in line with NICE TA</p> <p>Fostemsavir- Proposed as RED in line with NHSE commissioning</p> <p>Maribavir- Proposed as RED in line with NICE TA</p>			
2023.10.06	Feedback from Integrated Medicines Optimisation Committee	<p>Discussions on Shared care frameworks</p> <p>New migraine drug</p> <p>National Medicine optimisation</p> <p>Homecare and its issues</p> <p>Sodium valproate- Risks and the responsibilities for risk assessment</p> <p>KMc would like the item (Valproate) to be added to the action tracker as a priority for patient safety</p>	Noted		
2023.10.07	Work plans	<p>a) Joint formulary alignment</p> <p>b) Shared care frameworks</p> <p>c) Guidelines</p>	Ongoing for information only		
2023.10.08	Ratification of guidelines and SCFs	<p>a) Azithromycin Amber Guidance- clarification needed on GP/consultant responsibilities. Anti-microbial group to be shown paper</p> <p>b) Ranolazine Amber Guidance- confirm classification, proposed as Amber 2 in line with York but on joint formulary as Amber 1 – add to joint formulary agenda to discuss</p> <p>c) Just in case Medication leaflet – AK to contact GPs GPs at St Andrews hospice</p> <p>d) Wound Management Formulary CHCP</p> <p>e) Administration of Red and Amber Drugs within Integrated Nursing</p> <p>f) Specialist Infant Formulae</p>	<p>a) Update and send to next APC</p> <p>b) update and send to JF for review of classification</p> <p>c) Approved with additions of contact details and</p> <p>d) Approved</p> <p>e) Approved</p> <p>f) Approved</p> <p>g) Approved to review classification at joint formulary</p>	JM	10/23

		g) Dienogest pathway h) Rifaximin Amber Guidance	h) Approved with minor updates		
2023.10.09	Ratification of joint formulary	<ul style="list-style-type: none"> • Nil this month 			
2023.10.10	RTDC updates	<ul style="list-style-type: none"> • August 23- to update formulary 	Update formulary/red list	JM/LS/AK	11/23
2023.10.11	Minutes from subcommittees	a) Joint formulary subcommittee (Nil this month) b) Guideline subcommittee (July 2023)	Attached for info only		
2023.10.12	Additional minutes for information	a) HUTH D&TC (July 2023) b) HFT DTG (Nil) c) NLAG M&T (Nil) d) NYY APC (Nil)	Attached for info only		
2023.10.13	Correspondence received	<ul style="list-style-type: none"> • Dosulepin- Discussion over item use for a local patient. Write to GP with the guidance of reduce and change item if needed 			
2023.10.14	AOB	KMc raised point of Needle cost and adding statement to formulary around KMc discussed new migraine drug as MHRA approved can be used though patient funded. Agreed that item should go to local drug and therapeutics committee with an application Inclisiran- GP unsure how to order- within guidance			
2023.10.15	Date of next meeting	1 st November 13.00 – 15.00 Teams			